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Background: Lipopolysaccharide (LPS) has shown heterogeneous effects on 
eosinophilic inflammation in airways. However, little is known about how LPS 
regulates pathogenesis of chronic rhinosinusitis with nasal polyps, a major form of 
eosinophilic inflammation in the upper airway. 
Objective: We sought to investigate the effect of LPS on cytokine production by 
dispersed nasal polyp cells (DNPCs). 
Methods: Either diclofenac-treated or untreated DNPCs were cultured with or without 
staphylococcal enterotoxin B (SEB) in the presence or absence of LPS, after which the 
levels of IL-5, IL-13, IL-17A and IFN-γ within the supernatant were measured. The 
effects of PGE2 on LPS-induced responses by diclofenac-treated DNPCs were also 
examined. LPS-induced PGE2 production and mRNA expression of COX-1, COX-2 and 
microsomal PGE2 synthase-1 (m-PGES-1) were measured. 
Results: SEB induced IL-5, IL-13, IL-17A and IFN-γ production by DNPCs. 
Pretreatment with LPS prior to SEB stimulation inhibited production of these cytokines. 
After stimulation with LPS, PGE2 production and expression of COX-2 and m-PGES-1 
mRNA by DNPCs increased significantly. In the presence of diclofenac, the suppressive 
effects of LPS were eliminated. LPS pretreatment enhanced SEB-induced IL-5, IL-13 
and IL-17A production in diclofenac-treated DNPCs, while addition of PGE2 inhibited 
IL-5, IL-13 and IFN-γ production. LPS alone induced IL-5, IL-13 and IFN- γ production 
by diclofenac-treated DNPCs, while the addition of EP2 and EP4 receptor-selective 
agonists, as well as PGE2 itself, inhibited IL-5 and IL-13 production. 
Conclusions & Clinical Relevance: These results suggest that the regulatory effects of 
LPS on eosinophilic airway inflammation are controlled via the COX-2/PGE2 axis. For 
clinical implications, indiscreet use of non-steroidal anti-inflammatory drugs should be 
avoided in patients with CRSwNP. 
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Chronic rhinosinusitis with nasal polyps (CRSwNPs) is characterized by eosinophilic 
inflammation, and is often associated with asthma and aspirin sensitivity [1]. While the 
precise etiology and pathophysiology underlying this disease remains poorly understood, 
imbalances in local Th1, Th2, Th17 and Treg responses appear to be involved [2, 3]. 
Components and products derived from microbes including viruses, fungi and 
bacteria can exert cellular responses in CRSwNP [4-7]. For example, we demonstrated 
that Staphylococcus aureus enterotoxin B (SEB) and crude extracts of fungi including 
Aspergillus, Alternaria and Candida induced IL-5 and IL-13 production by dispersed 
nasal polyp cells (DNPCs) [5, 7]. In addition, regulatory role of COX pathway in these 
responses has been investigated [3, 5, 7].  
Lipopolysaccharide (LPS), a ubiquitous cell wall component of gram-negative 
bacteria, is known to participate in the pathogenesis of CRSwNPs, particularly mucin 
production [8]. Exposure to LPS showed heterogeneous effects on eosinophilic 
inflammation in the airway [9-12]. Experimental studies have demonstrated that 
exposure to LPS suppresses eosinophilic inflammation by immune deviation towards 
Th1 responses or triggering nitric oxide synthase 2 activity [9, 10]. In contrast, a 
significant increase in eosinophil count was seen in nasal/bronchial lavage fluid 
following exposure to allergen and LPS in patients with allergic asthma [11, 12]. 
However, little is known about whether LPS affects eosinophilia-associated cytokine 
production reflecting Th responses in CRSwNP. 
In order to determine whether the exposure to LPS affects the 
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pathogenesis of CRSwNP, we investigated the effects of LPS on SEB-induced Th1, 
Th2 and Th17-associated cytokine production using a recently developed ex vivo model 
[3, 5]. In addition, we investigated the role of COX metabolism, particularly PGE2, in 
the regulatory effects of LPS on SEB-induced cytokine production by DNPCs, as LPS 
is known to induce COX expression and PGE2 production in various cells and organs 
including nasal epithelial cells from patients with CRS [13-15]. We believe that the 
present findings provide new insight into the role of LPS in the pathogenesis of 







Materials and methods 
Patients 
Fourteen Japanese patients (age range, 15-72 years; median age, 41.5 years; 11 men and 
3 women) with CRSwNP were studied. CRSwNP was defined using the diagnostic 
criteria of Benninger et al. [16]. 4 patients were asthmatic, and none were thought to 
exhibit aspirin intolerance based on their history of asthma attacks precipitated by 
non-steroidal anti-inflammatory drugs. All patients were resistant to medical 
treatment, including macrolide therapy, and thus had endonasal sinus surgery. None of 
the participants received systemic glucocorticoids for a period of at least 8 weeks prior 
to surgery, and none received pharmacotherapy for sinusitis, such as macrolide 
antibiotics or intranasal glucocorticoids, for a period of at least 3 weeks prior to surgery. 
Informed consent for participation in the study was obtained from each patient, and the 
study was approved by the Human Research Committee of the Okayama University 
Graduate School of Medicine, Dentistry and Pharmaceutical Sciences. 
 
Antigen and reagents 
We purchased the following study materials: SEB (Toxin Technology, Sarasota, FL); 
LPS, RPMI-1640, L-glutamine-penicillin-streptomycin solution, protease, collagenase 
(Type I), hyaluronidase, DNase I, and SQ22536 (Sigma, St. Louis, MO); diclofenac 
sodium (Wako Pure Chemicals, Osaka, Japan); FCS (Invitrogen, Carlsbad, CA); red 
blood cell lysis buffer (Roche, Indianapolis, IN); and PGE2 (Cayman, Ann Arbor, MI). 
The receptor-selective agonists for EP1, (ONO-DI-004), EP2 (ONO-AE1-259-01), EP3 
(ONO-AE-248) and EP4 (ONO-AE1-329) were provided by Ono Pharmaceuticals 
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(Osaka, Japan). PGE2 and EP receptor-selective agonists were dissolved to a stock 
concentration of 10-2 M in DMSO (Sigma) and stored at -80°C until use. 
 
Preparation of DNPCs 
DNPCs were prepared from nasal polyps by enzymatic digestion, as described 
previously [5]. Briefly, minced nasal polyps were incubated for 2 hours at 37°C in 
RPMI 1640 (1 g tissue per 4 ml) containing 2.0 mg/ml protease, 1.5 mg/ml collagenase, 
0.75 mg/ml hyaluronidase and 0.05 mg/ml DNase. The cell suspension was then filtered 
through a 70-μm cell strainer (BD Falcon, Bedford, MA) in order to remove any 
undigested tissue, and was washed twice with washing medium (RPMI 1640 
supplemented with 2% FCS, 2 mM glutamine, 100 U/ml penicillin and 100 μg/ml 
streptomycin). The cell pellet was resuspended in erythrocyte lysis buffer and washed 
with washing medium. After washing, DNPCs were suspended in culture medium 
(RPMI 1640 supplemented with 10% heat-inactivated FCS, 2 mM glutamine, 100 
U/ml penicillin and 100 μg/ml streptomycin). 8.5 ± 5.3%, 11.7 ± 8.9%, 8.9 ± 8.2%, 8.5 
± 6.8%, 7.8 ± 11.1%, 10.9 ± 10.5%, 15.5 ± 6.7%, and 21.6 ± 7.7% cells in DNPC 
express c-kit, ECP/EPX, CD79α, CD68, CD4, CD8, cytokeratin, and vimentin, 
respectively [5]. DNPCs were immediately used for the following experiments after the 
preparation. 
 
Cell cultures and cytokine determination 
In flat-bottomed 48-well culture plates (Asahi Techno Glass, Tokyo, Japan), 500 μl of 
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1×106/ml DNPCs were stimulated with 1 ng/ml SEB at 37°C in a 5% CO2/air mixture 
because our preliminary study indicated that 72 hours’ incubation is the optimal 
period to induce a substantial production of IL-5 by DNPCs without microbial 
contamination. The culture supernatant was collected after 72 hours and stored at 
-80°C, after which levels of IL-5, IL-13, IL-17A and IFN-γ were determined by ELISA 
[3, 5]. Levels of IL-5, IL-13 and IFN-γ were measured using Opt EIA sets (BD 
Biosciences), according to the manufacturer’s instructions. Levels of IL-17A were 
measured using a DuoSet ELISA development kit (R&D Systems, Minneapolis, MN). 
The detection limit of these assays was 4 pg/ml for IL-5, 2 pg/ml for IL-13, 8 pg/ml for 
IL-17A and 4 pg/ml for IFN-γ. 
 
Effects of LPS on SEB-induced cytokine production by DNPCs 
DNPCs were pretreated with LPS at 0.2 or 2.0 μg/ml 2 hours prior to SEB stimulation 
in order to explore the effects of LPS on SEB-induced cytokine production by DNPCs. 
Alternatively, 0.2 μg/ml LPS was added to the culture at 1, 12 or 24 hours after SEB 
stimulation. To determine the role of COX and PGE2 in the effect of LPS on 
SEB-induced cytokine production, DNPCs were pretreated with 10-5 M diclofenac in the 
presence or absence of 10-6 M PGE2 or control buffer (0.05% DMSO) prior to LPS 
treatment.  
 
Effects of COX and PGE2 on LPS-induced cytokine production by DNPCs 
DNPCs were solely cultured with and without 0.2 μg/ml LPS for 72 hours, after which 
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levels of cytokines were determined. To determine whether COX and PGE2 are 
involved in LPS-induced cytokine production, DNPCs were pretreated with 10-5 M 
diclofenac or SC-791 (Merk KGaA, Darmstadt, Germany), a selective COX-2 
inhibitor, in the presence or absence of 10-6 M PGE2, four EP receptor-selective 
agonists or control buffer (0.05% DMSO). Our preliminary study showed that 
DMSO concentrated from 0.001% to 0.1% had no significant effect on the viability 
of DNPCs for either 24 hours or 72 hours incubation as determined by trypan blue 
dye exclusion test. To determine adenylate cyclase activity, DNPCs were incubated 
with SQ22536, an inhibitor of adenylate cyclase, at 370C for 1 hour. Following 
incubation, the cells were washed with culture medium twice, after which they 
were treated with diclofenac in the presence of either PGE2 or control buffer, then 
the cells were stimulated with LPS. 
 
Effects of LPS on COX-mediated PGE2 metabolism in DNPCs 
In order to determine whether LPS affects COX-mediated PGE2 metabolism, 1×106/ml 
DNPCs (n=8) were cultured in the presence or absence of 0.2 μg/ml LPS for 2 and 24 
hours. Extraction of total cellular RNA, reverse transcription to generate cDNA, and 
real-time quantitative PCR for COX-1, COX-2 and microsomal PGE2 synthase-1 
(m-PGES-1) was then performed, as described previously [17]. The amounts of 
GAPDH, for which primers were purchased from Toyobo (Osaka, Japan), were used as 
an internal control. The absolute copy number for each sample was calculated, and 
samples were reported as copy numbers relative to GAPDH. The concentration of PGE2 
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in the supernatants after 72 hours culture with 0.2 μg/ml LPS in DNPCs (n=9) was also 
determined using a PGE2 EIA kit (Cayman). The detection limit was 7.8 pg/ml. 
 
Statistical analysis 
The data were looked as ratio to baseline, and values are given as medians. 
Nonparametric Mann-Whitney U test was used to compare data between groups, and 
Wilcoxon signed-rank test was used for analysis within groups. One-way 
repeated-measures ANOVA and multiple comparisons with Bonferroni method was 
used to examine the data among three or more groups. P values of less than 0.05 were 
considered to be statistically significant. Statistical analyses were performed with SPSS 







Pretreatment with LPS inhibits SEB-induced Th1/Th2/Th17 cytokine production by 
DNPCs 
We have previously shown that SEB induced not only Th2-associated IL-5 and IL-13 
production, but also Th17-assciated IL-17A production by DNPCs [3, 5]. In the present 
study, we confirmed that DNPCs produced a substantial amount of IFN-γ in response to 
SEB (p<0.001, Fig. 1). 
Pretreatment with 0.2 μg/ml LPS 2 hours prior to SEB stimulation significantly 
inhibited SEB-induced IL-5 (25.1% inhibition, p<0.001), IL-13 (30.6% inhibition, 
p<0.001), IL-17A (13.6% inhibition, p=0.022) and IFN-γ (28.0% inhibition, p=0.002) 
production by DNPCs (Fig. 1). The presence of asthma did not affect the inhibitory 
role of LPS on SEB-induced cytokine production (data not shown). On the other 
hand, addition of 0.2 μg/ml LPS after SEB stimulation had no inhibitory effect on 
cytokine production, except for IL-5 production with LPS treatment at 1 hour after SEB 
stimulation (p=0.012) (Fig. 2). Rather, addition of LPS at 24 hours after SEB 
stimulation significantly enhanced SEB-induced IFN- γ production (p=0.036, Fig. 2D). 
Thus, we used LPS at a concentration of 0.2 μg/ml for further analysis.  
 
LPS induces COX and PGE2 expression in DNPCs 
In order to determine how pretreatment with LPS exerts its inhibitory effects on 
SEB-induced cytokine production, we focused on the COX-mediated PGE2 pathway. 
The amount of COX-1 mRNA was not significantly altered after stimulation with 
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LPS (Fig. 3A). However, the amount of COX-2 mRNA in DNPCs increased 
significantly at 2 hours after stimulation with LPS (p=0.012, Fig. 3B), and this increase 
was sustained at 24 hours (p=0.012, Fig. 3B). The amount of m-PGES-1 mRNA was 
increased at 24 hours but not at 2 hours post stimulation with LPS (p=0.012, Fig. 
3C). At the functional level, DNPCs displayed a significant increase in PGE2 
production in response to LPS for 72 hours (p=0.021, Fig. 3D). 
 
COX-derived PGE2 displays a crucial role in the inhibitory effects of LPS on 
SEB-induced cytokine production 
Based on the above information, we examined whether COX blockade affects the 
inhibitory effects of LPS on SEB-induced cytokine production. Treatment with 
diclofenac significantly enhanced SEB-induced IL-5 (p<0.001) and IL-13 (p=0.012) 
production and conversely suppressed SEB-induced IL-17A production (p<0.001), 
validating our previous studies (3, 5). There was a trend for enhanced SEB-induced 
IFN-γ production by diclofenac treatment (p=0.075). 
In the presence of diclofenac, the suppressive effects of pretreatment with LPS 
on SEB-induced cytokine production were blocked. Rather, LPS pretreatment 
significantly enhanced SEB-induced IL-5 (p=0.019, Fig. 4A), IL-13 (p=0.006, Fig. 4B) 
and IL-17A (p=0.026, Fig. 4C) production. There was a trend for enhanced 
SEB-induced IFN-γ production (p=0.064, Fig. 4D). 
As compared with control buffer, addition of 10-6 M PGE2 significantly 
reversed the enhancement by diclofenac on SEB-induced IL-5 (p=0.008, Fig. 4A), 
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IL-13 (p=0.008, Fig. 4B) and IFN-γ (p=0.008, Fig. 4D) production by LPS-pretreated 
DNPCs. These results were similar to the effect when we pretreated cells with LPS 
in Fig. 1. On the other hand, IL-17A production was further increased in the presence of 
PGE2 (p=0.011, Fig. 4C). 
 
COX-derived PGE2 controls LPS-induced cytokine production by DNPCs via 
EP2/EP4-mediated pathway 
Finally, we investigated whether LPS alone induced cytokine production in DNPCs. 
Stimulation with 0.2 μg/ml LPS did not induce significant production of IL-5 (p=0.117, 
Fig. 5A), IL-13 (p=0.209, Fig. 5B), IL-17A (p=0.655, Fig. 5C) or IFN-γ (p=0.062, Fig. 
5D) by DNPCs. However, in diclofenac-treated DNPCs, LPS significantly induced IL-5 
(p=0.001, Fig. 5A), IL-13 (p=0.002, Fig. 5B) and IFN- γ (p=0.003, Fig. 5D) production. 
LPS stimulation did not affect IL-17A production by DNPCs, even in the presence of 
diclofenac (p=0.593, Fig. 5C). Treatment with SC-791, a selective COX-2 inhibitor, 
also significantly induced IL-5 (p=0.007), IL-13 (p=0.005) and IFN- γ (p=0.013) but 
not IL-17A (p=0.944) production by LPS-stimulated DNPCs, suggesting that 
LPS-induced COX-2 is involved in the pathogenesis of CRSwNP. 
Addition of PGE2 significantly inhibited LPS-induced IL-5 (p=0.022, Fig. 6A) 
and IL-13 (p=0.022, Fig. 6B) production, but not IL-17A (p=0.109, Fig. 6C) or IFN- γ 
(p=0.213, Fig. 6D) production by diclofenac-treated DNPCs. When we used four EP 
receptor-selective agonists, one-way repeated-measures ANOVA showed that treatment 
with these agonists significantly altered LPS-induced IL-5 (p=0.007) and IL-13 
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(p=0.007) production by diclofenac-treated DNPCs. Treatment with EP2 (p=0.014) and 
EP4 (p=0.047) receptor-selective agonist significantly suppressed the IL-5 production. 
Treatment with EP2 and the EP4 receptor selective agonist also showed a tendency to 
inhibit the IL-13 production (p=0.055 and p=0.085, respectively, Fig. 6F). 
Pretreatment with SQ22536 significantly reversed the inhibitory effect of PGE2 on 







In the present study, we investigated the regulatory effects of LPS on SEB-induced 
Th1-, Th2- and Th17-associated cytokine productions in ex vivo model of CRSwNP. 
Our results demonstrated that exposure to LPS induced a substantial suppression in 
SEB-induced IL-5, IL-13, IFN-γ and IL-17A production in a dose and phase-dependent 
fashion, whereas this exposure inversely increased these productions when the COX 
pathway was blocked. Moreover, LPS itself induced IL-5, IL-13 and IFN-γ production, 
but not IL-17A production, by DNPCs when the COX pathway was blocked, and 
addition of PGE2 blocked LPS-induced IL-5 and IL-13 production. Taken together with 
the finding that LPS enhanced expression of COX-2 and m-PGES-1 mRNA, as well as 
production of PGE2 in DNPCs, the main advancement in knowledge offered by this 
study is that the regulatory effect of LPS on the pathogenesis of CRSwNP is 
critically regulated by COX/PGE2 axis.  
 IL-5 and IL-13 are major Th2 cytokines associated with eosinophilic 
inflammation [18]. High levels of IL-5 in nasal secretions are a specific biomarker for 
CRSwNP [19]. It has been reported that the exposure to LPS can either protect or 
exacerbate eosinophilic inflammation [9-12]. The present results support both findings, 
and suggest that the detrimental or alleviative effects of LPS on eosinophilic 
inflammation in CRSwNP are dependent on the activation of the COX pathway. In 
addition, EP2 and EP4 receptor-selective agonists, as well as PGE2 itself, cancelled 
LPS-induced IL-5 and IL-13 production by diclofenac-treated DNPCs. It is known that 
PGE2 is able to inhibit eosinophilic inflammation and Th2 cytokine production [8, 20]. 
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Together with the finding that the pretreatment with SQ22536 significantly 
cancelled the effect of PGE2, the present results suggest that LPS-induced PGE2 
through COX-2 activation displays a critical role in controlling eosinophilic 
inflammation via cAMP-dependent EP2- and EP4-mediated pathways in CRSwNP. 
In addition, we have previously reported that m-PGES-1 was selectively expressed 
on CD68+ cells in nasal polyps, suggesting that nasal polyp macrophages are 
involved in the regulatory effects of LPS on these cytokine productions. 
 The characterization and role of IFN-γ, the major Th1 cytokine, in the 
pathogenesis of CRSwNP has been recently clarified [21, 22]. Our results suggest that 
exposure to LPS inhibits not only Th2 responses but also Th1 responses induced by 
SEB in DNPCs. The inhibition of SEB-induced IFN- γ production by LPS may be 
mediated by the induction of PGE2 by LPS, as PGE2 is known to suppress IFN-γ 
production under various conditions [23, 24]. The present findings further suggest that 
the inhibitory effect of LPS on SEB-induced eosinophilia-associated Th2 cytokine 
productions is not attributable to Th1/Th2 cross-regulation. In Fig. 1D, one patient 
showed an outlier response of increased IFN-γ production in response to 
pretreatment with 0.2 μg/ml LPS. Since the patient did not exhibit infection on 
board or increased neutrophilia in nasal polyps, the reason for this outlier response 
was unclear. 
 Similar to IL-5 and IL-13, LPS alone did not affect IFN-γ production by 
DNPCs, but induced IFN-γ production when COX was blocked. On the other hand, 
unlike IL-5 and IL-13, addition of PGE2 did not block LPS-induced IFN-γ production in 
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diclofenac-treated DNPCs. Although the production of IFN-γ in response to LPS was 
modest, these results suggest that prostanoids other than PGE2 have a potent inhibitory 
effect on LPS-induced IFN-γ production. 
 IL-17A is a major Th17 cytokine expressed by macrophages, CD4+ T cells, and 
eosinophils in NPs, and its expression is correlated with the degree of eosinophilia in 
sinonasal tissues [3, 25]. Exposure to LPS also inhibits IL-17A production induced by 
SEB in DNPCs. However, this inhibition is marginal as compared with IL-5, IL-13 and 
IFN-γ. In addition, LPS did not induce IL-17A production by DNPCs either with or 
without COX blockade. Although IL-17A can be produced by exposure to LPS both in 
vivo and in vitro, our results suggest that the inhibitory effect of LPS on SEB-induced 
Th17 response was weak as compared with Th1 and Th2 responses [26]. 
Unlike IL-5, IL-13 and IFN-γ, addition of PGE2 enhanced the effects of LPS on 
SEB-induced IL-17A production by diclofenac-treated DNPCs. This is consistent with 
recent reports showing that PGE2 promotes IL-17A production and Th17 differentiation 
[3, 27]. For example, we recently showed that PGE2 enhanced SEB-induced IL-17A 
production by diclofenac-treated DNPCs [3]. One of the reasons why pretreatment 
with LPS inhibits SEB-induced IL-17A production despite PGE2 further increase 
IL-17A production from LPS and SEB stimulated cells in the presence of 
diclofenac, may be that LPS-induced prostanoids contrary to PGE2 may have an 
inhibitory effect on SEB-induced IL-17A production. 
The present study demonstrated that the inhibitory effects of LPS on 
SEB-induced cytokine productions were dose- and phase-dependent. Exposure to LPS 
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after SEB stimulation had little effects on SEB-induced cytokine production. This is 
consistent with a recent report demonstrating that exposure to LPS after the first 
immunization with allergen has little effect on allergen tolerance, thus suggesting that 
pre-exposure to LPS is critical for the inhibitory effects on SEB-induced cytokine 
productions [28]. 
Various concentrations of LPS were used for human in vitro and/or ex vivo 
studies. Nanogram quantities of LPS are normally used in subcultured cell lines 
including human nasal fibroblasts [29]. However, microgram quantities of LPS are 
often used in freshly-isolated bulk cell lines including peripheral blood 
mononuclear cells and cord blood mononuclear cells [30, 31]. Since DNPCs were 
also freshly-isolated bulk cell lines, we think that 0.2 μg/ml is an acceptable 
concentration to analyze the effect of LPS in the present study. 
In conclusion, LPS can play both a beneficial and a harmful role in the 
pathology of CRSwNP, and LPS-derived COX-2/PGE2 axis is critically involved. 
Several reports demonstrate that regular use of non-steroidal anti-inflammatory 
drugs (NSAIDs) increases the risk of adult-onset asthma [32, 33]. For clinical 
implications, although there is no any clinical evidence that NSAIDs treatment can 
increase symptoms (rhinorrhea, nasal obstruction, anosmia), polyp size or number 
of polypectomies, the present ex vivo study may suggest that avoidance of 
indiscreet regular use of NSAIDs is preferable for patients with CRSwNP. In 
addition, these observations may provide a basis for novel therapeutic approaches 
targeting LPS and other components of microbes the management of eosinophilic 
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Figure 1. Effects of pre-treatment with LPS on SEB-induced cytokine production by 
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DNPCs. DNPCs were treated with 0, 0.2 or 2.0 μg/ml LPS 2 hours prior to SEB 
stimulation. After 72 hours of incubation with SEB, levels of IL-5 (A), IL-13 (B), 
IL-17A (C) and IFN-γ (D) within the supernatant were determined. The data were 
looked as difference from baseline. Bars represent median values. P values were 
determined using Wilcoxon signed-rank test. 
 
Figure 2. Effects of post-treatment with LPS on SEB-induced cytokine production by 
DNPCs. At 1, 12 or 24 hours after SEB stimulation, DNPCs were exposed to 0.2 μg/ml 
LPS. After 72 hours of incubation with SEB, levels of IL-5 (A), IL-13 (B), IL-17A (C) 
and IFN-γ (D) were determined. Bars represent median values. The data were looked 
as difference from baseline. P values were determined using Wilcoxon signed-rank 
test. 
 
Figure 3. Effects of LPS on expression of COX-related molecules in DNPCs. DNPCs 
were cultured with or without 0.2 μg/ml LPS for 2 or 24 hours, and relative amounts of 
COX-1 (A), COX-2 (B) and m-PGES-1 (C) mRNA were determined. Alternatively, 
levels of PGE2 after 72 hours of incubation with LPS were measured (D). The data 
were looked as difference from baseline. Bars represent median values. P values were 
determined using Wilcoxon signed-rank test. 
 
Figure 4. Effects of LPS and PGE2 on SEB-induced cytokine production in the presence 
of diclofenac. Diclofenac-treated DNPCs were exposed or unexposed to LPS prior to 
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SEB stimulation (left side of each graph). Under these conditions, either 10-6M PGE2 or 
control buffer was added to the culture (right side of each graph). Levels of IL-5 (A), 
IL-13 (B), IL-17A (C) and IFN-γ (D) were determined and changes from baseline were 
expressed. The data were looked as difference from baseline. Bars represent median 
values. P values were determined using Wilcoxon signed-rank test. 
 
Figure 5. Effects of diclofenac on LPS-induced cytokine production by DNPCs. 
Diclofenac-treated or untreated DNPCs were cultured with or without 0.2 μg/ml LPS 
for 72 hours. Levels of IL-5 (A), IL-13 (B), IL-17A (C) and IFN-γ (D) were determined. 
The data were looked as difference from baseline. Bars represent median values. P 
values were determined using Wilcoxon signed-rank test. 
 
Figure 6. Effects of PGE2 and EP-selective agonists on LPS-induced cytokine 
production by diclofenac-treated DNPCs. Diclofenac-treated DNPCs were cultured with 
LPS in the presence of either 10-6M PGE2 (A-D), EP-selective agonists (E-H) or control 
buffer for 72 hours. Levels of IL-5 (A, E), IL-13 (B, F), IL-17A (C, G) and IFN-γ (D, H) 
within the supernatant were determined. The data were looked as difference from 
baseline. Bars represent median values. P values were determined using Wilcoxon 
signed-rank test (A-D) and One-way repeated-measures ANOVA and multiple 
comparisons with Bonferroni method (E-H). 
 
Figure 7. Reversal of inhibitory effect of PGE2 on LPS-induced IL-5 and IL-13 
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production by diclofenac-treated DNPCs with adenylate cyclase inhibitor. DNPCs 
were pretreated with SQ22536 at 370C for 1 hour. Following incubation, the cells 
were washed with culture medium twice, after which they were treated with 
diclofenac in the presence of either PGE2 or control buffer, then the cells were 
stimulated with LPS for 72 hours. Levels of IL-5 (A) and IL-13 (B) within the 
supernatant were determined. Bars represent median values. P values were 
determined using Wilcoxon signed-rank test. 







